January 10, 2024 4:40pm

At the JPM healthcare conference; buying pre the presentation and selling post continues as momentum declines exponentially

Join me … in the NO spin zone.

Pre-open Indications: 6 Hits and 1 Miss

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.

Never leave an investor uninformed! A trusted source of factual reporting!

With no sigh of relief today, I answer or qualify equity’s thrown dice, in which company should investors put or keep in their portfolio for the near and long term


Wednesday: The Dow closed UP +170.57 points or +0.45%, the S&P closed UP +26.95 points or +0.57% while the Nasdaq closed UP +111.94 points or +0.75%



We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes traded higher Wednesday, with investors awaiting the release of fresh U.S. inflation data and earnings.


52-week low:

Mesoblast (MESO) drops -$0.14 to $1.96 after a 1 for 2 split.

  • Mesoblast Limited (MESO and ASX: MSB), who have seen the share price tank a massive 89% over a 3-year period. The share price down 68% in a year. Furthermore, it's down 21% in about a quarter.


Wednesday’s Pre-Open: RegMed Investors’ (RMi) pre-open: “JPM Healthcare conference day#3, the past curse of the conference; buying pre the presentation and selling post. Reiterating, “Who will have a seat when the presentations begin, which will benefit from the investment gamut after when the music stops or slows? As uncle algo and his electronic trading dwarf’s collect from the upsiders.” … https://www.regmedinvestors.com/articles/13280


Pre-Open Indications: 6 Hits < Alnylam Pharmaceuticals (ALNY -$2.22), Sage Therapeutics (SAGE -$1.07), Ultragenyx Pharmaceuticals (RARE +$1.29), Vericel (VCEL -$0.22), Caribou Bioscience (CRBU +$0.18), CRISPR Therapeutics (CRSP +$0.08)> 1 Miss < AxoGen (AXGN -$0.30)>  


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences 

  • Wednesday’s advance/decline line was negative at the open with 12 incliners, 22 decliners and 1 flat, ending with a negative close of 14 incliners, 21 decliners and 0 flat


Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q1/24: 1 holiday, 4 negative and 3 positive closes


  • 1 holiday, 10 negative and 10 positive closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 12 negative and 10 positive closes


Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was down -0.71% and the XBI was down -1.14%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.05 point or -0.39% at 12.71


Wednesday’s Closing Down (10 of 21):

  • Alnylam Pharmaceuticals (ALNY -$1.59 after Tuesday’s +$1.37 after Monday’s +$7.45
  • Ultragenyx Pharmaceuticals (RARE -$1.19 after Tuesday’s -$1.43 after Monday’s +$2.18
  • Sage Therapeutics (SAGE -$0.97 after Tuesday’s +$1.27 after Monday’s +$3.63
  • Beam Therapeutics (BEAM -$0.88 after Tuesday’s +$0.10 after Monday’s +$1.79),
  • Ionis Pharmaceuticals (IONS -$0.67 after Tuesday’s +$0.56 after Monday’s +$1.62)
  • Voyager Therapeutics (VYGR -$0.46 after Tuesday’s -$0.19),
  • Intellia Therapeutics (NTLA -$0.41 after Tuesday’s -$0.78 after Monday’s +$1.44),
  • Prime Medicine (PRME -$0.33),
  • BioLife Solutions (BLFS -$0.27),
  • AxoGen (AXGN -$0.25 after Tuesday’s -$0.12),

Wednesday’s Closing Up (10 of 14):

  • CRISPR Therapeutics (CRSP +$0.71),
  • Generation Bio (GBIO +$0.26),
  • Editas Medicine (EDIT +$0.24 after Tuesday’s -$0.19),
  • Caribou Biosciences (CRBU T+$0.22 after Tuesday’s $0.00)
  • Blueprint Medicine (BPMC +$0.21 after Tuesday’s -$2.33 after Monday’s +$2.34
  • Regenxbio (RGNX +$0.20),
  • Fate Therapeutics (FATE +$0.16 after Tuesday’s +$0.26),
  • MiMedx (MDXG +$0.07 after Tuesday’s -$0.19),
  • Harvard Apparatus RN (HRGN +$0.07 after Tuesday’s -$0.27 after Monday’s $0.00)
  • Graphite Bio (GRPH +$0.05),


Q1/24 – January

  • Wednesday closed negative with 14 incliners, 21 decliners and 0 flat


The BOTTOM LINE: the cell and gene therapy sector showed another touch of weakness on Wednesday after Tuesday’s decline.

  • Back from the good old days of JPM Healthcare conference boosting appeal to cell and gene therapy companies … which came with Tuesday’s volatility and more than a few of sector downfalls!
  • As the Nasdaq gained +0.75% on Wednesday after Tuesday’s gain of +0.09% post Monday’s +2%.


Some News from the JPM Healthcare:  Nothing “leaks” for my coverage “unit”


But remember, “News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!” <me>


Coming Attractions: today and tomorrow …

  • Investors are gearing up for the December consumer price index report due on Thursday. It is expected to show that headline inflation rose 0.2% in the month and by 3.2% on an annual basis.,
  • Investors are also anxious to see U.S. company quarterly results, which begin with reports from some of the big U.S. banks on Friday.
  • Benchmark 10-year yields edged lower after a 10-year note auction. They were last up at 4.037%.

The top three (3) performing in the session:

  • Wednesday:  Blueprint Medicine (BPMC), Generation Bio (GBIO) and Caribou Biosciences (CRBU)
  • Tuesday: Vericel (VCEL), Solid Biosciences (SLDB) and Alnylam Pharmaceuticals (ALNY),
  • Monday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Blueprint Medicine (BPMC)

The worst three (3) in the session:

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE) and Beam therapeutics (BEAM)
  • Tuesday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Intellia Therapeutics (NTLA)
  • Monday: Regenxbio (RGNX), Homology Medicine (FIXX) and Agenus (AGEN)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.